Abstract
Objective To investigate the efficacy of hysteroscopic tubal catheterization with methotrexate combined with mifepristone on tubal pregnancy and its influence on ovarian function and fertility outcome. Methods The data of 200 patients with tubal pregnancy were analyzed, and the 200 patients were divided into treatment group and control group, with 100 cases in each group. The patiens in control group were treated with mifepristone, and the patients in treatment group were treated by injecting oviduct under hysteroscope and methotrexate combined with mifepristone. The curative effect, ovarian function, fertility outcome and adverse reactions were compared between the two groups. Results After treatment, the cure rate of experimental group was significantly higher than that of the control group (91% vs 79%) (P<0.05); after treatment, the ovarian antral follicle number, ovarian function normal rate in experimental group were higher than the control group (P<0.05); the pregnancy rate of intrauterine test group was significantly higher than those of the control group (90% vs. 79%) (P<0.05); the ectopic pregnancy rate in experimental group was significantly lower than that of the control group (8% vs. 15%) (P<0.05); the total non pregnant rate in experimental group was significantly lower than that in the control group (2% vs. 6%); the adverse reaction rate in experimental group was significantly lower than that in the control group (7% vs. 16%) (P<0.05). Conclusions The effect of hysteroscopic tubal catheterization and injection of methotrexate combined with mifepristone on tubal pregnancy is obvious, and it can improve the ovarian function and fertility outcomes of patients, and the incidence of adverse reactions is low, so it is worthy of clinical application. Key words: Tubal pregnancy; Methotrexate; Mifepristone; Ovarian function; Fertility outcome
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call